Clinical Significance of the Serum Anti - C1q Antibody in Evaluating the Activity of Systemic Lupus Erythematosus and the Pathological Type of Lupus Renal

崔婵娟,柏明见,冯珍如,闫存玲,李志艳,牛飞
DOI: https://doi.org/10.3969/j.issn.1007-9572.2014.17.016
2014-01-01
Chinese General Practice
Abstract:Objective To explore the relationship between serum anti - Clq antibody and the activity of systemic lupus erythematosus(SLE)as well as the pathological type of LN,showing its clinical value in aided diagnosis of SLE and LN and judgment of its activity. Methods By ELISA,serum anti - C1q antibody were detected in 120 SLE patients〔including 59 ca-ses with LN(LN group)and 61 cases without LN(non - LN group);61 active patients(active group)and 59 remission pa-tients(remission group)〕,100 patients with other autoimmune diseases( disease control group)and 120 healthy individuals (healthy control group)from Peking University First Hospital,December 2012 to August 2013. Anti - C1q antibody were com-pared in these different groups,and were analyzed with anti - dsDNA antibody,complement and SLEDAI. Results The posi-tive rate of serum anti - C1q antibody in SLE group was significantly higher than that in disease control group and healthy control group〔35. 8% (43 / 120)vs. 12. 0% (12 / 100),P ﹤ 0. 017;35. 8% (43 / 120)vs. 5. 0% (6 / 120),P ﹤ 0. 017〕. The positive rate and the level of serum anti - C1q antibody in the SLE active group were both significantly higher than those in the SLE remission group〔49. 2% (30 / 61)vs. 22. 0% (13 / 59),P ﹤ 0. 05;11. 68(3. 19,19. 37) U/ ml vs. 3. 76(1. 93, 8. 28)U/ ml,P ﹤ 0. 05〕. The positive rate and the level of serum anti - C1q antibody were both not significant in SLE different active groups(P ﹥ 0. 05). The positive rate of anti - C1q antibody in LN was significantly higher than that in non LN group〔50. 8% (30 / 59)vs. 21. 3% (13 / 61),P ﹤ 0. 05〕. The positive rate of serum anti - C1q antibody in Class Ⅳ LN patients was higher than that in Class Ⅱ ﹢ Ⅲ LN patients〔68. 8% (22 / 32)vs. 23. 5% (4 / 17),P ﹤ 0. 017〕. The sensitivity of anti- C1q antibody in the diagnosis of LN was lower than that of anti - dsDNA antibody 〔 50. 85% ( 37. 64% ,63. 95% ) vs. 69. 49% (55. 98% ,80. 46% )〕,but the specificity of anti - C1q antibody in diagnosis of LN was higher than that of anti -dsDNA antibody〔78. 69% (65. 98% ,87. 74% )vs. 57. 38% (44. 10% ,69. 73% )〕. If anti - C1q antibody and anti - ds-DNA antibody were combined detection,the specificity in diagnosis of LN could be increased to 88. 52% ( 77. 17% , 94. 88% ). The serum anti - C1q antibody was positively correlated with the SLEDAI and the level of anti - dsDNA antibody(r= 0. 293,P ﹤ 0. 01;r = 0. 305,P ﹤ 0. 01),and negatively correlated with complement C3 and C4 (r = - 0. 290,P ﹤ 0. 01;r = - 0. 283,P ﹤ 0. 01). Conclusion The serum anti - C1q antibody,a simple,specific and non - invasive biomarker,can objectively reflect the disease activity of SLE and effectively guide the clinical judgment of the LN pathological types,particularly diffuse proliferative LN(class Ⅳ). The serum anti - C1q antibody and anti - dsDNA antibody combined can improve LN diag-nostic specificity.
What problem does this paper attempt to address?